GlassScriptPhysician profile
Tiffany A Richards
NPI 1154499713
$36,938.67
in general payments reported to CMS, 2019-2025
13 companies · $5,874 in 2025
The $5,874 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11K · 2022: $4,804 · 2023: $11K · 2024: $4,219 · 2025: $5,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,627 · Grant: $3,927 · Travel and Lodging: $2,775 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,400 · Honoraria: $990 · Food and Beverage: $969 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,627.00 |
| Grant | $3,927.28 |
| Travel and Lodging | $2,774.91 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,400.00 |
| Honoraria | $990.00 |
| Food and Beverage | $968.87 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12,850.00 | 2021-2023 | |
| Pfizer INC. | $8,625.39 | 2021-2025 | |
| Janssen Global Services, LLC | $4,350.00 | 2023 | Rybrevant, Darzalex, Tecvayli |
| Genzyme Corporation | $3,933.72 | 2023-2025 | |
| Celgene Corporation | $2,357.00 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $2,020.70 | 2022-2024 | |
| Janssen Biotech, INC. | $1,052.06 | 2021-2025 | Talvey, Carvykti |
| Regeneron Pharmaceuticals, INC. | $987.00 | 2025 | Lynozyfic |
| E.R. Squibb & Sons, L.L.C. | $500.00 | 2021 | |
| Legend Biotech USA INC. | $203.55 | 2023-2025 | Carvykti |
| Daiichi Sankyo INC. | $27.63 | 2024 | Vanflyta |
| Ethicon US, LLC | $19.08 | 2023 | N/A |
| Novo Nordisk INC | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.